Showing results (111-120 of 218) with videos related to
Sort By:
Pageof 22
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.The Journal of Experimental Medicine|November 25, 2024
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancerCamila Robles-Oteíza, Katherine Hastings, Jungmin Choi, et al.Leukemia|January 12, 2020
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual diseaseG A Horne, J Stobo, C Kelly, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2019
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung CancerSiwen Hu-Lieskovan, Aaron Lisberg, Jesse M Zaretsky, et al.The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.Annals of Internal Medicine|May 1, 1997
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancerS Vadhan-Raj, L J Murray, C Bueso-Ramos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.The Lancet. Oncology|December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.Pageof 22